IngentaConnect Intranasal fluticasone propionate reduces ICAM-1 on nasal epithel...

Abstract:

Background

Allergen specific nasal challenge (ASNC) is an optimal method to study the pathophysiological mechanisms sustaining the allergic inflammation and in particular the adhesion molecule system, which is involved in cellular infiltration of nasal mucosa. Topical steroids have been accepted as a highly effective anti-inflammatory therapy for allergic rhinitis. Objective

The aim of this double-blind placebo- controlled study was the evaluation of clinical and cytological parameters, including ICAM-1 expression on nasal epithelial cells, after a 4 week treatment with nasal fluticasone propionate (200 μg/daily) or placebo, using the model of ASNC. Methods

Twenty allergic rhinitics underwent nasal challenge before and after treatment. The following parameters were evaluated: (i) nasal symptoms (rhinorrhoea, itching, sneezing, obstruction), (ii) inflammatory cells (eosinophils and neutrophils), (iii) ICAM-1 expression on nasal epihelial cells at baseline, 30 min (early phase) and 6 h (late phase) after ASNC. Results

Fluticasone propionate was capable of reducing: (i) clinical symptoms during both early (P < 0.001) and late phase (P < 0.04), (ii) eosinophil (P < 0.002) and neutrophil (P < 0.001) infiltrate during late phase, and (iii) ICAM-1 expression on nasal epithelial cells during both early (P < 0.01) and late phase (P < 0.03). Conclusions

The present results demonstrate that fluticasone propionate exerts a significant action on early and late phase clinical events following specific nasal challenge, reducing also the cellular influx during the late phase. This event is likely due to the modulation of ICAM-1 expression on epithelial cells.

Keywords: nasal challenge; adhesion molecules; fluticasone propionate; allergic inflammation

Document Type: Original article

DOI: 10.1046/j.1365-2222.1998.00239.x

Affiliations: 1: Allergy and Clinical Immunology Service, Department of Internal Medicine, University of Genoa, 2: Koelliker Hospital, Turin, 3: Medical Department, Glaxo-Wellcome, Verona, Italy

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax Refund Policy

Intranasal fluticasone propionate reduces ICAM-1 on nasal epithelial cells both during early and late phase after allergen challenge